<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101747</url>
  </required_header>
  <id_info>
    <org_study_id>XC2</org_study_id>
    <nct_id>NCT04101747</nct_id>
  </id_info>
  <brief_title>To Explore the Diversity of Intestinal Flora in Patients With Advanced HCC Combin ed With Anti-PD-1 and Targeted Drug Therapy and the Correlation Between Metabolites and Therapeutic Effect</brief_title>
  <official_title>To Explore the Diversity of Intestinal Flora in Patients With Advanced Hepatocellular Carcinoma Receiving Anti-PD-1 Combined With Targeted Drug Therapy and the Correlation Between Metabolites and Therapeutic Effect:A Multi-Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to explore the correlation between intestinal flora diversity and meta bolites&#xD;
      in patients with advanced lver cancer rceiving Anti-PD-1 combined target-ed drug therapy,so&#xD;
      that to get the analysis of intestinal flora of PD-1 inhibitors in liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of PD-1/PD-L1 inhibitors and targeted drugs as a promising strategy for the&#xD;
      treatment of hepatocellular carcinoma has a breakthrough significance for the treatment of&#xD;
      some advanced and refractory tumors.However,studies have shown that intestinal flora&#xD;
      diversity indicates a good prognosis of PD-1/PD-L1 inhibitors in the treatment of non-small&#xD;
      cell lung cancer, the intestinal flora analysis of PD-1 inhibitors in hepatocellular&#xD;
      carcinoma is still a new field to be explored.&#xD;
&#xD;
      This study is to select patients who meet the criteria of entry and discharge, sign informed&#xD;
      consent, obtain patients'clinical data, pathological and case data, and enter the database.&#xD;
      Before the treatment of PD-1 (no more than 24 hours), during the treatment of PD-1 (every&#xD;
      time before treatment, three weeks, a total of 11 follow-up visits), at the end of treatment,&#xD;
      fecal samples were collected in sterile containers for 5-10g, and feces were stored at 4&#xD;
      degrees C, frozen at - 80 degrees C within 24 hours; the response to treatment was evaluated&#xD;
      every 6 weeks, and the disease was first evaluated clinically. The patients were divided into&#xD;
      response group (R) (partial response or stable condition) or non-response group (NR) (disease&#xD;
      progression) according to RECIST 1.1 evaluation criteria. Subgroup had high diversity of&#xD;
      bacteria and low diversity of bacteria, and were observed continuously until the end of&#xD;
      treatment. The bacterial ribosomal DNA was extracted, metabolites were detected and flow&#xD;
      cytometry was used to analyze the data. The baseline intestinal microflora diversity,&#xD;
      microflora diversity mapping, continuous Shannon index curve change mapping were compared&#xD;
      between groups and within groups, and correlation validation was carried out.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (RR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>To analyse the Objective response rate (RR) of patients with advanced HCC receiving anti-PD-1 combined with targeted drug therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>To exprole the Disease control rate (DCR) of patients with advanced HCC receiving anti-PD-1 combined with targeted drug therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of intestinal flora</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>To exprole the Number of intestinal flora of patients with advanced HCC receiving anti-PD-1 combined with targeted drug therapy</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Before the treatment of PD-1 (no more than 24 hours), during the treatment of PD-1 (every&#xD;
      time before treatment, three weeks treatment, a total of 11 follow-up visits), at the end of&#xD;
      treatment, fecal samples were collected in sterile containers for 5-10 g, feces were stored&#xD;
      at 4 C, frozen at - 80 C within 24 hours.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Include patients who meet the entry and discharge criteria, obtain patients'clinical data,&#xD;
        pathological and case data, enter the database, collect fecal samples of 5-10g, evaluate&#xD;
        the response to treatment every 6 weeks, and conduct data analysis, compare the baseline&#xD;
        intestinal microflora diversity between and within groups, microflora diversity mapping,&#xD;
        continuous Shannon fingers. Number curve mapping, attention to follow-up patients, record&#xD;
        treatment, progress, other toxic and side effects and combined drug use information.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients signed informed voluntary enrollment and expected survival of more than 12&#xD;
             weeks;&#xD;
&#xD;
          -  Patients with HCC confirmed by histopathology or cytology or clinic are HBV-related&#xD;
             HCC;&#xD;
&#xD;
          -  No systematic treatment for HCC has been received in the past, excluding local&#xD;
             chemotherapy drugs used in TACE/TAI;&#xD;
&#xD;
          -  Not suitable for surgical treatment;&#xD;
&#xD;
          -  Child-Pugh Class: Grade A or B (≤7 points);&#xD;
&#xD;
          -  BCLC stage C;&#xD;
&#xD;
          -  ECOG PS≤1;&#xD;
&#xD;
          -  At least one measurable lesion (according to RECIST v1.1 requirement, the length of&#xD;
             spiral CT of the lesion is ≥10mm or the short diameter of enlarged lymph nodes is ≥15&#xD;
             mm);&#xD;
&#xD;
          -  Organ Function Requirements (within 7 days before treatment):&#xD;
&#xD;
        Blood routine examination: WBC (&gt;1.5 *109/L); PLT (&gt;75 *109/L); HB (&gt;90 g/L); no blood&#xD;
        transfusion within 14 days before screening, G-CSF drug correction) Liver function tests:&#xD;
        ALB (&gt; 29 g/L); TBiL (&lt; 1.5 * ULN); ALT, AST, AKP (&lt; 5 * ULN); INR (&lt; 2.3) or PT (&lt; 6&#xD;
        seconds) exceeding normal control Renal function: Cr &lt; 1.5 ULN or CCr &gt; 50 mL/min&#xD;
&#xD;
          -  Patients with active hepatitis B virus (HBV) infection: must receive anti HBV&#xD;
             treatment;&#xD;
&#xD;
          -  Fertility women should abstinence or use reliable methods of contraception during the&#xD;
             observation of curative effect. Serum HCG test must be negative within 7 days before&#xD;
             the study treatment, and must be non-lactating. When it comes to abstinence, partners&#xD;
             should also have reliable and effective contraception;&#xD;
&#xD;
          -  Assessment of patients who are eligible for anti-PD-1 combined with targeted drug&#xD;
             therapy;&#xD;
&#xD;
          -  Consent to sign informed consent and follow up for a long time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar&#xD;
             cell carcinoma; other active malignant tumor except HCC within 5 years or&#xD;
             simultaneously;&#xD;
&#xD;
          -  Patients with moderate or severe ascites need therapeutic puncture and drainage or&#xD;
             Child score &gt; 2 (except those with small amount of ascites without clinical symptoms);&#xD;
&#xD;
          -  Patients with a history of gastrointestinal bleeding or risk of bleeding within 6&#xD;
             months before the start of the study, such as severe esophageal varices, locally&#xD;
             active gastrointestinal ulcer lesions, and positive persistent fecal occult blood;&#xD;
&#xD;
          -  Known hereditary or acquired bleeding or thrombotic tendency, thrombosis or embolism&#xD;
             occurred within 6 months before treatment, and aspirin &gt; 325 mg/day was taken within&#xD;
             10 days before treatment;&#xD;
&#xD;
          -  It is known that there is a history of severe allergy to any monoclonal antibody or&#xD;
             anti-angiogenesis targeted drug;&#xD;
&#xD;
          -  Severe infections occurred within 4 weeks before the start of the study, including but&#xD;
             not limited to hospitalization due to infections, bacteremia or complications of&#xD;
             severe pneumonia;&#xD;
&#xD;
          -  Previous treatment with other anti-PD-1 antibodies or other immunotherapy against&#xD;
             PD-1/PD-L1;&#xD;
&#xD;
          -  Complicated with other hepatitis virus infection or alcoholic liver disease,&#xD;
             hereditary metabolic liver disease, autoimmune liver disease and other liver diseases;&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency (HIV, or treatment with immunosuppressive&#xD;
             agents or systemic hormones within 14 days before treatment (&gt;10mg/d prednisone or&#xD;
             other hormones)&#xD;
&#xD;
          -  There are cardiopulmonary diseases that can not be well controlled, such as cardiac&#xD;
             insufficiency above NYHA II or LVEF &lt; 50% by color Doppler echocardiography, COPD with&#xD;
             repeated pulmonary infections.&#xD;
&#xD;
          -  Intravenous antibiotics or prophylactic antibiotics were given in the past month.&#xD;
             -Receive immunopotentiation therapy, such as thymosin, Ridaxian, etc.&#xD;
&#xD;
          -  Other factors that may affect the results of the study or lead to the forced&#xD;
             termination of the study, such as alcoholism, drug abuse, other serious diseases&#xD;
             (including mental disorders) requiring combined treatment, accompanied by family or&#xD;
             social factors, may affect patient safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chan Xie, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Affliated Hosoital of Sun Yat-Sun University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chan Xie, Professor</last_name>
    <phone>8620-85252043</phone>
    <email>happyxiechan@hotmail.com</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 22, 2019</study_first_submitted>
  <study_first_submitted_qc>September 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 22, 2019</last_update_submitted>
  <last_update_submitted_qc>September 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Chan Xie</investigator_full_name>
    <investigator_title>Professor of department of infectious disease Third Affiliated Hospital,Sun Yat-Sen University</investigator_title>
  </responsible_party>
  <keyword>Advanced hepatocellular carcinoma</keyword>
  <keyword>Combination of PD-1/PD-L1 Inhibitors and Targeted Drugs</keyword>
  <keyword>Diversity of intestinal flora</keyword>
  <keyword>Metabolites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

